BioSeek will apply its proprietary BioMap systems in an effort to characterize the mechanisms of action of the leukocyte selective anti-inflammatory drugs (LSAIDs), which make up Inflazyme's respiratory program.
BioSeek's BioMap systems are a series of human primary-cell based assay systems designed to replicate the intricate cell and pathway interactions present in human disease biology. Depending on their mechanism of action, compounds induce specific patterns of changes in these systems (BioMap profiles) that can be compared to a large number of reference profiles in BioSeek's database.
“This is a particularly good match since BioSeek's technology includes systems that cover human disease biology relevant to asthma, COPD, allergy and other inflammatory conditions, key areas of focus for Inflazyme,” said Dr Kevin Mullane, president and chief executive officer of Inflazyme.